BOSTON--(BUSINESS WIRE)--Parthenon Therapeutics, a biotech company inventing a novel class of anti-cancer therapies that reprogram the tumor microenvironment (TME), today announced the appointment of Joseph Paul Eder, MD, as Chief Medical Officer.
“We are excited to welcome Dr. Joseph Paul Eder to Parthenon as Chief Medical Officer. Dr. Eder joins us at an important time in the growth of Parthenon, as we prepare to advance our lead drug candidate, PRTH-101, into the clinic, advance our clinical strategy, and continue to scale our pipeline of first-in-class therapeutics," said Laurent Audoly, Ph.D, co-founder, Chief Executive Officer, and Chairman of the Board of Directors, Parthenon Therapeutics. “Parthenon is focused on advancing the right drug for the right patient. Our focus on precision medicine requires the seamless integration of insights into our mechanistic hypothesis, biomarker deployment, and clinical development. This is exemplified through Dr. Eder’s record of accomplishment in the development of anti-cancer therapeutics, most recently as Clinical Director at Yale Unversity’s Cancer Center. Dr. Eder has excelled in areas such as autologous bone transplant, modulation and reversal of drug resistance, cell cycle inhibitors, and the therapeutic use of anti-angiogenesis agents. His experience also extends to the pharmaceutical industry where he was Senior Medical Science Director & Global Clinical Medical Director, Hematology at AstraZeneca, PLC.”
“As member of Parthenon’s Clinical Advisory Board, I was impressed by the potential of the company’s unique approach, which can modulate the tumor microenvironment thereby making tumors shrink and become more susceptible to immune attack across a number of preclinical models,” said Dr. Eder. “This approach opens the door to an entirely new approach to treat immune-excluded tumors, either as a single agent or in combination with checkpoint inhibitors and beyond, and ultimately extending and improving the lives of cancer patients. As Chief Medical Officer, I look forward to working with the Parthenon team and our outstanding Scientific and Clinical Advisory Boards to invent and develop new therapies for patients.”
About Dr. Eder
Dr. Eder is Chief Medical Officer at Parthenon, bringing over 30 years of clinical experience at leading cancer research institutions as well as the pharmaceutical industry. Most recently, Dr. Eder was Clinical Director of the Early Drug Development Program as well as Professor at the Yale School of Medicine. From 2010 to 2012, Dr Eder was Medical Science Director, Disease Area Clinical Expert, Hematology, AstraZeneca, PLC as well as Associate Clinical Professor, Harvard Medical School, Boston, MA. Dr. Eder was Clinical Discovery Sr. Director, Oncology, AstraZeneca, PLC from 2009 to 2012, prior to which he was Medical Science Director at AstraZeneca. From 2005 to 2010, Dr. Eder was Associate Professor, Harvard Medical School and from 2003 to 2007 was Clinical Director, Clinical Research Center at the Dana-Farber Cancer Institute. He was Clinical Director, Experimental Therapeutics & Translational Pharmacology, Dana-Farber Harvard Cancer Center from 1998 to 2007, and was Assistant Professor, Harvard Medical School from 1988 to 2004. From 1985 to 1988 Dr. Eder was Instructor, Harvard Medical School. Dr. Eder was awarded his MD from Georgetown University School of Medicine.
About Parthenon Therapeutics
Parthenon Therapeutics is inventing a novel class of anti-cancer therapies that reprogram the tumor microenvironment (TME). The interplay between cancer cells and their surrounding microenvironment is relevant in drug development as many cancers use the TME to build barriers that shield immune system attack. One approach, PRTH-101, breaks these barriers to overcome recalcitrant cancers. Based on rigorous, groundbreaking research, we are designing a portfolio of drug candidates to treat the right patients at the right time. For more information visit parthenontx.com and LinkedIn.